How many bispecific antibodies drugs are tracked?

Drug Landscape tracks 7 bispecific antibodies (3 marketed, 0 Phase 3, 4 Phase 2, 0 Phase 1).

How fresh is this page?

Refreshed every 30 minutes from primary sources (Drugs@FDA, EMA EPAR, ClinicalTrials.gov, sponsor 8-K filings).

Bispecific Antibodies — Pipeline, Approvals, Sponsors

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Engineered antibodies binding two targets simultaneously. T-cell engagers (BiTEs, TCB) bridge CD3 on T cells to a tumour antigen. Blincyto, Tepkinly, Talvey, Elrexfio.

Marketed

Filed

Phase 3

Phase 2

Phase 1

Total

Marketed leaders

2023-01-01 — Elrexfio · Pfizer · Bispecific antibody · Oncology
2023-01-01 — Elrexfio · Pfizer · Oncology
— Pf-07826390 · Pfizer · Unknown · Other

Recent approvals (last 30 days)

No approvals in the last 30 days.

Upcoming PDUFA (next 180 days)

No upcoming PDUFA in next 180 days.

Top sponsors in this modality

Pfizer Inc. · 4 bispecific antibodies
Pfizer · 3 bispecific antibodies

Drug classes within Bispecific Antibodies

Bispecific antibody · 1
Unknown · 1

Subscribe to ongoing alerts

Push every new bispecific antibodies event into your RSS reader:

Other modalities

Biologics Monoclonal Antibodies Small Molecules Antibody-Drug Conjugates Cell Therapies Gene Therapies Gene Editing mRNA Therapeutics siRNA Therapeutics Antisense Oligonucleotides Vaccines

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing